Tegoprazan-d6

Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases[1][2][3].

Product Specifications

Product Name Alternative

CJ-12420-d6; RQ-00000004-d6

UNSPSC

12352005

Target

Na+/K+ ATPase; Proton Pump

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Solubility

10 mM in DMSO

Smiles

CC1=NC2=C(C=C(C=C2N1)C(N(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)O[C@H]3CCOC4=C3C(F)=CC(F)=C4

Molecular Formula

C20H13D6F2N3O3

Molecular Weight

393.42

References & Citations

[1]Takahashi N, Take Y. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. J Pharmacol Exp Ther. 2018 Feb;364 (2) :275-286.